Shots:

• Gadeta will receive an up front, near-term option fee & research milestones & is eligible to receive development & commercial milestones along with royalties if Immunocore exercises its option for an exclusive license
• Under the research collaboration, Immunocore to get an option to develop ImmTAC therapies from ‘201 TCR & get an exclusive license option to research, develop & commercialize ImmTAC candidates
• The agreement combines Gadeta’s gamma delta target & TCR identification expertise with Immunocore’s TCR bispecific engineering, development & commercialization capabilities to develop γδ-ImmTAC therapies. GDT201 showed promising results in the pre-clinical studies in colorectal cancer cell lines & the P-I trial is expected to initiate in H2’23 for solid tumor

Ref: Compass Therapeutics | Image: Compass Therapeutics